The company's biotherapeutics platform includes novel T-cell receptors, regulatory T-cells, and universal engineered T-cell platforms that control T-cell activation and direction, as well as proprietary technologies to activate, expand, and genetically engineer T-cells from peripheral blood, cord blood, and tumors. Their team of experts in T-cell biology, manufacturing, regulatory affairs, and clinical development has a proven track record of executing safe and effective cell and gene therapy clinical trials. Tmunity is advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases, and autoimmune disease. The company is now part of Kite, a Gilead Company, which has more patient experience than any other cell therapy company.